Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- The Number of Applicants Increases 779 to 5911 for MR Exam
October 20, 2011
- Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
- JGA President Sawai Insists on Keeping 70% Rule for New Generics
October 19, 2011
- Vaccine Industry Must Continue to Present Proposals t oGov’t: Mr Fushimi of JAVI
October 18, 2011
- Dispensing Fees May Be Cut to Enable Hike in Medical Fees: Mr Urushibata of Chuikyo
October 18, 2011
- JPA Opposes TPP on Fears of Drug Safety
October 14, 2011
- Osteoporosis Foundation Survey Shows Patient Interest in Monthly BP Formulation
October 14, 2011
- CSMIC’s Kobayashi Questions Proposal to Freeze NHI Prices
October 12, 2011
- 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
- Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
- OPMA to Develop Projects for Kansai Innovation Special area
October 11, 2011
- JACDS to Propose Reforms to Promote Switch-OTC Progress in Japan
October 11, 2011
- Association-managed Pharmacies Should Become “Home Healthcare Support Centers”: Mr Kodama of JPA
October 11, 2011
- JPA Announces FY2010 Results of Drug Event Monitoring for SU Drugs
October 11, 2011
- JPMA to Work with IFPMA to Tackle Non-communicable Diseases in Developing World
October 10, 2011
- Speed, Quality of Clinical Trials Have Increased: Mr Kawaguchi of JPMA
October 10, 2011
- Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
- Permanent Introduction of Premium for New Drug Development Is an Option: Executive Director Miura of JPA
October 3, 2011
- Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
- “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…